Point Roberts, WA, New York, NY - August 7, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a technical trading alert for Aethlon Medical, Inc. (OTCQB: AEMD). The stock had a technical breakout and a significant 5 day run. Following breaking through its 52 week high of $.020, it traded up over 40% in yesterdays session to close at $0.27 on strong volume and momentum.

On July 18 th Zacks Small Cap Research issued an update entitled AEMD: Recent Progress Helps De-Risk Aethlon by Brian Marckx, CFA. The report included a pricing target for the stock that has since been surpassed.

Investors have reacted to a stream of positive news in the past several weeks including

FDA approval of an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.

Additionally the company announced a contract from the Defense Advanced Research Projects Agency, or DARPA, including partners Battelle, NxStage Medical (NASDAQ: NXTM), that represents a four year $22.83 million deal to design, develop, test and validate an advanced, portable medical device.

The most recent update was an announcement that the European Patent Office has provided Aethlon with a Decision to Grant a Patent entitled "METHOD OF REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS” has taken the stock to a new technical trading pattern.

The European Patent will be assigned Patent No. 1624784 and has been referenced in European Patent Office Bulletin No. 13/29.

About Aethlon Medical (OTCQB: AEMD)

Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.

Zacks research link:

http://finance.yahoo.com/news/aemd-recent-progress-helps-risk-110000781.html

About InvestorIdeas.com: Big Ideas for global investors

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.

Follow Investorideas.com on Twitter   http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas

Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com

Sign up for free stock alerts

http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech and medical technology stocks:

http://www.investorideas.com/membership/

Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

800-665-0411 or 212-822-8842Source - www.Investorideas.com